Aclaris Therapeutics ACRS Return on equity

Return on equity at other companies

IncyteINCY

30.7%+6.4pp

Corvus PharmaceuticalsCRVS

-30.5%-12.5pp

Upstream Bio, Inc.UPB

-46%—

Avalo TherapeuticsAVTX

-36.3%—

Shattuck Labs, Inc.STTK

-39.2%-12.5pp

Cullinan Therapeutics, Inc.CGEM

-44%+26.2pp

FAQ

What is Aclaris Therapeutics's return on equity?

Aclaris Therapeutics (ACRS) reported return on equity of -59.1% in Q2 2026.

How has Aclaris Therapeutics's return on equity changed year-over-year?

Aclaris Therapeutics's return on equity increased by 41.7% year-over-year, from -101.4% to -59.1%.

What is the long-term trend for Aclaris Therapeutics's return on equity?

Over 5 years (2020 to 2025), Aclaris Therapeutics's return on equity has grown at a -11.9% compound annual growth rate (CAGR), from -94.9% to -50.2%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.